TruNativ lands $30M Series B from OrbiMed, plots D2C-to-pharmacy push and Gulf entry

Mumbai nutrition brand TruNativ raised $30M Series B led by OrbiMed to scale D2C, quick commerce, modern trade and pharmacy, with UAE and Singapore launches by year-end. FY25 revenue hit ₹125 crore; FY26 target ₹200 crore as it chases share in a $1.62B Indian protein market growing 6.54% CAGR.

— Source publishedTue, 16 Jun, 2026, 17:05 IST·First seen Tue, 16 Jun, 2026, 17:08 IST·Source Mint · Companies

What happened

Mumbai-based nutrition brand TruNativ raised $30M Series B led by OrbiMed to expand D2C, quick commerce, modern trade and pharmacy distribution, plus UAE and

Key facts

  • $30 million Series B
  • ₹125 crore FY25 revenue
  • ₹200 crore FY26 target
  • 19% Emami stake
  • $1.62B India protein market 2026
  • 6.54% CAGR

Why this matters

TruNativ's simultaneous push into pharmacy distribution and GCC markets makes it a credible roll-up anchor or strategic target for global nutrition majors seeking India-Gulf corridor exposure before the next funding round resets valuation.

Also reported by